Shanghai-based private equity and venture capital firm Decheng Capital is raising up to $450 million for its third fund that will invest in the life sciences sector, according to a filing at the US Securities and Exchange Commission (SEC).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
